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Abstract
Background: Endothelial cells play a complex role in the pathobiology of cancer. This role is not limited to the
making of blood vessels to allow for influx of oxygen and nutrients required for the high metabolic demands of
tumor cells. Indeed, it has been recently shown that tumor-associated endothelial cells secrete molecules that
enhance tumor cell survival and cancer stem cell self-renewal. The hypothesis underlying this work is that specific
disruption of endothelial cell-initiated signaling inhibits tumor growth.
Methods: Conditioned medium from primary human dermal microvascular endothelial cells (HDMEC) stably
transduced with silencing RNA for IL-6 (or controls) was used to evaluate the role of endothelial-derived IL-6 on the
activation of key signaling pathways in tumor cells. In addition, these endothelial cells were co-transplanted with
tumor cells into immunodefficient mice to determine the impact of endothelial cell-derived IL-6 on tumor growth
and angiogenesis.
Results: We observed that tumor cells adjacent to blood vessels show strong phosphorylation of STAT3, a key
mediator of tumor progression. In search for a possible mechanism for the activation of the STAT3 signaling
pathway, we observed that silencing interleukin (IL)-6 in tumor-associated endothelial cells inhibited STAT3
phosphorylation in tumor cells. Notably, tumors vascularized with IL-6-silenced endothelial cells showed lower
intratumoral microvessel density, lower tumor cell proliferation, and slower growth than tumors vascularized with
control endothelial cells.
Conclusions: Collectively, these results demonstrate that IL-6 secreted by endothelial cells enhance tumor growth,
and suggest that cancer patients might benefit from targeted approaches that block signaling events initiated by
endothelial cells.
Keywords: Cervical Cancer, Signaling pathways, Molecular targeted therapy, STAT3
Background
Uterine cervix carcinoma (UCC) includes malignant le-
sions arising from the tissues of the cervix, and repre-
sents the 3rd most common cancer in women worldwide
with approximately 529,800 new cases diagnosed every
year [1]. The three major histological types of invasive
cervical cancer are squamous cell carcinoma (SCC),
adenocarcinomas (AC) and adenosquamous carcinoma
(ASC). SCC comprise 80% of cases, and adenocarcin-
omas and ASC comprise approximately 20% [1,2]. In de-
veloped countries, its incidence has showed a marked
decline over the past 40 years because of widespread
screening with cervical cytology. This decline is mainly
attributable to a decrease in the incidence of squamous
cell carcinoma [3-10]. On the other hand, there has been
a relative increase in the incidence of adenocarcinomas
and adenosquamous carcinoma of the cervix over the
same period. Notably, the pathobiology of adenocarcin-
omas remains unclear, particularly the impact of the
crosstalk between endothelial cells and tumor cells to
cancer growth and progression. Better understanding of
signaling events that mediate endothelial cell-tumor cell
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interactions will lead to the development of improved
therapies for uterine cervix adenocarcinomas.
Tumor progression requires the formation of new blood
vessels [11]. Therefore, several angiogenesis inhibitors
have been developed to target endothelial cells and block
tumor growth [12]. Targeting cells that support tumor
growth, rather than the cancer cells themselves, is an at-
tractive approach for cancer therapy. The vascular endo-
thelium is directly accessible to drugs injected in the
circulation, and is composed of cells that are more stable
genetically when compared to cancer cells [13-15]. Not-
ably, studies have suggested that both tumor and non-
tumor cells may be involved in reduced responsiveness to
therapy by developing acquired resistance [16]. Despite
significant advances in therapies targeting angiogenic mol-
ecules, the survival benefits of these treatments are rela-
tively modest [13], the treatments are costly [17], and have
significant side effects [18,19]. In addition, single-agent
therapy that is effective initially may ultimately lead to
drug resistance [20] and tumor recurrence.
The development of molecular targeted therapies may
lead to the rational selection of treatment for adenocar-
cinoma patients based on specific molecular mecha-
nisms whose deregulated activity contributes to the
initiation, development, and metastatic spread [21-24].
The deregulation of signaling cascades including the
transcription factor signal transducer and activator tran-
scription 3 (STAT3) pathway has been implicated in the
pathogenesis of cervical cancer [21]. Notably, the over-
expression of activated STAT3 is accompanied by poor
prognosis in this sub-group of tumors [22]. It is well
known that recombinant interleukin-6 (IL-6) induces
STAT3 activation [23]. However, the effect of endothelial
cell-secreted IL-6 on tumor cell STAT3 and overall
tumor growth is not known. The characterization of the
functional impact of the crosstalk between endothelial
cells and tumor cells on tumor growth and progression
may unveil endothelial cell-secreted molecules as a new
conceptual target for cervical cancer therapy.
The prevalent paradigm in tumor biology is that
tumor cells secrete factors that drive tumor growth and
that endothelial cells simply respond by generating new
blood vessels that support the high metabolic demands
of tumor cells. Here, we challenged this paradigm and
observed that endothelial cell IL-6 levels have a direct
impact on tumor cell phenotype and tumor growth
in vivo. Our results demonstrate that endothelial cell-
secreted IL-6 defines the growth of adenocarcinomas in
preclinical models.
Methods
Cell culture
Cervical adenocarcinoma cells (HeLa Cells) were cul-
tured in Dulbecco’s Modified Eagle Medium (DMEM;
Invitrogen, Carlsbad, CA) supplemented with 10% fetal
bovine serum (FBS), 100 U/ml penicillin, and 100 μg/ml
streptomycin (Invitrogen). Tumor cells were serum-
starved overnight before adding treatment. An immor-
talized human oral keratinocyte cell line (HOK-16B, gift
of No-Hee Park, University of California, Los Angeles)
was cultured in serum free medium (OKM; ScienCell,
Carlsbad, CA) containing 1% penicillin/streptomycin,
and supplemented with 5 μg/ml BSA, 5 μg/ml transfer-
ring, 50 μg/ml bovine pituitary extract, 2.5 μg/ml insu-
lin, 1 ng/ml FGF, 500 ng/ml epinephrine, 1 μg/ml
hydrocortisone, 30 nM prostaglandin, and 40 μg/ml
plant extract (OKGS, BulletKit, ScienCell). Primary hu-
man dermal microvascular endothelial cells (HDMEC;
Cambrex, Walkersville, MD) were cultured in endothe-
lial growth medium-2 (EGM2-MV; Cambrex). Condi-
tioned medium (CM) from HDMEC or HeLa were
prepared in endothelial cell medium (EBM) without
supplementation with growth factors or serum from
24-hour cultures.
Stable short hairpin RNA (shRNA) transduction
Lentiviruses expressing a short hairpin RNA (shRNA)
construct for silencing IL-6 (Vector Core, University of
Michigan) were generated in human embryonic kidney
cells (293 T) transfected by the calcium phosphate
method, as described [25]. A scrambled oligonucleotide
sequence (shRNA-C) was used as control. Supernatants
were collected 48 hours after transfection and used to in-
fect HDMEC in 1:1 dilution medium containing 4 μg/ml
polybrene (Sigma-Aldrich, St. Louis, MO). Cells were se-
lected in EGM2-MV supplemented with 1 μg/ml puro-
mycin (InvivoGen, San Diego, CA). Downregulation of
IL-6 was confirmed by ELISA.
Western blots
8 × 105 HeLa were plated in 60 mm dishes, starved over-
night, and exposed to EBM, or conditioned medium
(CM) collected from HDMEC or HeLa for the indicated
time points. HDMEC CM and HeLa CM were normal-
ized by total protein concentration. In addition, HOK-
16B were exposed to HDMEC CM. Alternatively, tumor
cells were exposed to rhIL-6 (BDP, NCI, Frederick, MD)
for the indicated time points. Signaling pathways were
blocked by pre-incubating tumor cells for 1-2 hours with
20 μM Stattic (STAT3 inhibitor V, Calbiochem, San
Diego, CA), 20 μM LY294002 (PI3 kinase inhibitor, Cell
Signaling Technology, Danvers, MA), or 20 μM U0126
(MEK1/2 inhibitor, Cell Signaling), as described [26],
and exposed to HDMEC CM or rhIL-6 for the indicated
time points. Lysates (30 μg) were electrophoresed in
SDS-polyacrylamide gels and transferred to nitrocellu-
lose membranes. Primary antibodies were: mouse anti-
human phospho-STAT3, rabbit anti-human STAT3,
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rabbit anti-human phospho-Akt, rabbit anti-human
Akt, rabbit anti-human phospho-ERK1/2, mouse anti-
human ERK1/2 (Cell Signaling); and mouse anti-
glyceraldehyde-3-phosphate dehydrogenase (GAPDH;
Chemicon, Millipore, Billerca, MA). Phosphorylation
antibodies detected endogenous levels of STAT3, Akt,
and ERK1/2 when phosphorylated at Tyrosine 705,
Serine 473, and Threonine 202/Tyrosine 204, respectively.
Immunoreactive proteins were visualized by Super-
Signal West Pico chemiluminescent substrate (Thermo
Scientific, Rockford, IL).
Enzyme-linked immunosorbant assay (ELISA)
Supernatants of endothelial or tumor cell cultures (24 hours)
were collected and centrifuged. IL-6 expression was deter-
mined using ELISA kits (Quantikine; R & D Systems,
Minneapolis, MN) according to the manufacturer’s instruc-
tions. Data were normalized by cell number.
SCID mouse model of human tumor angiogenesis
Xenograft human tumors vascularized with human
blood vessels were generated under an UCUCA ap-
proved protocol, as described [27-29]. Briefly, highly
porous poly-L(lactic) acid (Boehringer Ingelheim, Ingel-
heim, Germany) scaffolds were seeded with 9 × 105
HDMEC and 1 × 105 HeLa in a 1:1 mixture of growth
factor reduced Matrigel and EGM2-MV. In addition,
scaffolds were seeded with 9 × 105 HDMEC-shRNA-
control or HDMEC-shRNA-IL-6 and 1 × 105 HeLa. Se-
vere combined immunodeficient (SCID) mice (5-7-
week-old male CB.17.SCID; Charles River, Wilmington,
MA) were anesthetized with ketamine and xylazine, and
2 scaffolds were implanted in the subcutaneous space of
the dorsal region of each mouse, i.e. one scaffold seeded
with HDMEC-shRNA-control + HeLa and one scaffold
seeded with HDMEC-shRNA-IL-6 + HeLa. Tumors were
measured with a caliper every 2 days, starting at 14 days
after implantation. Mice were euthanized after 28 days,
implants were retrieved, photographed, measured,
weighed, fixed overnight in 10% buffered formalin at 4°C,
and embedded in paraffin following standard histo-
logical procedures. These studies were performed two
independent times to verify the reproducibility of the
work under a protocol reviewed and approved by the
University of Michigan Committee on Use and Care of
Animals (UCUCA). The total “n” of each experimental
condition was n = 12 tumors.
Immunohistochemistry of tissue sections
Immunohistochemistry was performed in paraffin-
embedded serial sections using phospho-STAT3 (Santa
Cruz), STAT3, phospho-Akt, Akt, phospho-ERK, ERK
(Cell Signaling), and Ki67 (Biocare Medical, Concord,
CA) antibodies, as described [30].
Tumor microvessel density
Tumor microvessel density was determined following
identification of blood vessels by immunohistochemistry
with a polyclonal anti-human factor VIII antibody (Lab
Vision, Fremont, CA), as previously described [27,28].
The number of stained microvessels was counted in 10
random fields per implant in a light microscope at 100×.
Twelve implants were analyzed per condition.
Statistical analyses
T-tests or one-way ANOVA followed by appropriate
post-hoc tests were performed using SigmaStat 2.0
(SPSS; Chicago, IL). Statistical significance was deter-
mined at P < 0.05.
Results
Endothelial cell-secreted factors activate key signaling
pathways in tumor cells
We have previously demonstrated that a crosstalk initi-
ated by endothelial cells enhances tumor cell survival
and migration in vitro, and that endothelial cell-derived
IL-6 induces phosphorylation of STAT3 in tumor cells
[26]. The overall hypothesis underlying this study is that
the activation of signaling pathways in tumor cells
induced by endothelial cell-secreted factors enhances
tumor growth. To begin to address this hypothesis,
we exposed HeLa cells to serum-free endothelial cell
(HDMEC) conditioned medium (CM) or tumor cell
(HeLa) CM and analyzed phosphorylation events over
time (Figure 1A). We observed that phosphorylation
levels of STAT3, Akt, and ERK were higher in tumor
cells exposed to HDMEC CM than in tumor cells ex-
posed to HeLa CM, or unconditioned medium (EBM).
The induction of phosphorylation was observed primar-
ily at early time points (15 to 30 minutes), decreasing at
1 hour (Figure 1A). Notably, expression levels of IL-6
were higher in HDMEC CM than in HeLa CM, and
silencing IL-6 in endothelial cells did not have a meas-
urable impact in endothelial cell proliferation (data
not shown). In addition, we analyzed phosphorylation
events on HeLa cells and on keratinocytes (HOK-16B)
exposed to HDMEC CM or unconditioned medium
(EBM) (Figure 1B). We observed that phosphorylation
levels of STAT3, Akt, and ERK were higher when both
tumor cells and keratinocytes were exposed to HDMEC
CM than to EBM. Similarly, phosphorylation was ob-
served mainly at early time points and decreased at
24 hours (Figure 1B).
To evaluate whether the trends of endothelial cell-
induced phosphorylation of STAT3, Akt, and ERK in
tumor cells in vitro translate into increased phosphoryl-
ation levels in vivo, we used the SCID mouse model
of human tumor angiogenesis in which we engineer
cervical cell adenocarcinomas vascularized with human
Neiva et al. BMC Cancer 2014, 14:99 Page 3 of 11
http://www.biomedcentral.com/1471-2407/14/99
functional blood vessels that anastomize with the mouse
vasculature [27-29]. We implanted highly porous bio-
degradable scaffolds containing primary human endothelial
cells (HDMEC) together with cervical adenocarcinoma
cells (HeLa) in the subcutaneous of SCID mice and ana-
lyzed the tissues by immunohistochemistry 28 days after
Figure 1 Endothelial cell-derived factors phosphorylate STAT3, Akt, and ERK in tumor cells in vitro and in vivo. A, western blot for
phosphorylated and total STAT3, Akt, and ERK in HeLa serum-starved overnight and exposed to HDMEC conditioned medium (CM), HeLa CM, or
control unconditioned medium (EBM) for the indicated time points. B, western blot for phosphorylated and total STAT3, Akt, and ERK in HeLa
or HOK-16B serum-starved overnight and exposed to HDMEC CM or EBM for the indicated time points. C, immunohistochemical analysis for phos-
phorylated STAT3, Akt, and ERK (with nuclear localization) in representative specimens from xenograft human squamous cell carcinomas.
Top panels represent 100× and lower panels represent 200× magnification. Red arrows point to blood vessels.
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transplantation. We observed that tumor cells adjacent to
blood vessels showed phosphorylation of STAT3, Akt, and
ERK (Figure 1C). In contrast, the expression of total
STAT3, Akt, and ERK was relatively uniform throughout
the tissues (data not shown).
Endothelial cell-induced STAT3 phosphorylation is
independent of Akt and ERK
To explore the interdependence of molecular signaling
events initiated by endothelial cells on tumor cells, we
exposed HeLa to HDMEC CM in the presence of chem-
ical inhibitors of STAT3, Akt, or ERK pathways and ana-
lyzed the interdependency of the phosphorylation
events. To establish the baseline for these experiments,
we exposed HeLa to HDMEC CM and analyzed phos-
phorylation of STAT3, Akt, and ERK with a detailed
time course up to 1 hour (Figure 2A). We observed that
HDMEC CM induces first ERK phosphorylation (with
strong activation as early as 1 minute, persisting until
15 minutes, and decreasing at 30 minutes), followed by
STAT3 and Akt (increasing until 15 minutes, and main-
taining activation for up to 1 hour) (Figure 2A). When
we inhibited STAT3 phosphorylation using the chemical
inhibitor Stattic, we did not observe significant changes
in phosphorylation of Akt or ERK (Figure 2B). However,
when we inhibited Akt phosphorylation using the PI3K
inhibitor LY294002 we observed an increase in ERK
phosphorylation levels (maintaining strong phosphoryl-
ation for up to 1 hour), while phosphorylation levels
of STAT3 did not change (Figure 2C). Similarly, when
we inhibited ERK phosphorylation using the MEK1/2
inhibitor U0126 we observed increased Akt phosphoryl-
ation (maintaining strong phosphorylation for up to
1 hour), whereas phosphorylation levels of STAT3
remained unchanged (Figure 2D).
Then, we extended the time course experiments to
24 hours, and observed the same relationship between
STAT3, Akt, and ERK phosphorylation in tumor cells in-
duced by endothelial cell-secreted factors (Additional file 1:
Figure S1). STAT3, Akt, and ERK phosphorylation were
stronger at early time points (15 to 30 minutes), and de-
creased over time. STAT3 phosphorylation decreased at
1 hour and was maintained for up to 24 hours, phos-
phorylation of Akt decreased at 2 hours and disappeared
at 4 to 24 hours, while phosphorylation of ERK de-
creased significantly at 1 hour and was absent at 3 to
24 hours (Additional file 1: Figure S1A). Inhibition of
STAT3 phosphorylation did not affect Akt or ERK phos-
phorylation levels (Additional file 1: Figure S1B). On the
other hand, inhibition of Akt phosphorylation increased
activation of ERK (Additional file 1: Figure S1C), and in-
hibition of ERK phosphorylation increased Akt activa-
tion (Additional file 1: Figure S1D). No major effect was
observed in STAT3 phosphorylation levels using Akt or
ERK inhibitors. Collectively, these studies demonstrated
that endothelial cell-induced Akt and ERK phosphoryl-
ation in tumor cells induce a mutually compensatory ef-
fect, while the STAT3 pathway is activated independently.
IL-6 induces the STAT3 signaling pathway in tumor cells
Considering the clinical relevance of the STAT3 signal-
ing pathway in cervical carcinoma [21,22] we focused
the remaining studies of this work on the effect of endo-
thelial cell-secreted IL-6 in the biology of adenocarcin-
oma cells. To understand the Cervical Adenocarcinoma
response to IL-6 stimulation, we performed a detailed
time course analyzing the phosphorylation events in
HeLa cells (Figure 3A). We observed that when tumor
cells were exposed to rhIL-6, the phosphorylation of
STAT3, Akt, and ERK followed similar patterns as when
tumor cells were exposed to HDMEC CM (Figure 1A;
Additional file 1: Figure 1A). We then exposed tumor
cells to IL-6 in the presence of chemical inhibitors of
STAT3, Akt, or ERK pathways and analyzed the phos-
phorylation responses (Additional file 1: Figure S2). IL-6
strongly activated STAT3 pathway in HeLa, and slightly
activated Akt or ERK (Additional file 1: Figure S2A).
Blockade of STAT3 phosphorylation had no major effect
on Akt but increased ERK phosphorylation (Additional
file 1: Figure S2B). Inhibition of Akt had no effect on
STAT3, while increased ERK phosphorylation (Additional
file 1: Figure S2C). Lastly, inhibition of ERK phosphoryl-
ation had no significant effect on STAT3 or Akt phos-
phorylation (Additional file 1: Figure S2D). Collectively,
these results showed that IL-6 is a potent inducer STAT3
signaling, while it has a weaker effect on the phosphoryl-
ation of Akt and ERK in Cervical Adenocarcinoma.
These results led us to further explore the IL-6/STAT3
signaling in vivo. We used the SCID mouse model of hu-
man tumor angiogenesis to generate human adenocarcin-
omas. We observed that while total STAT3 was present
diffusely through the entire tissue (Figure 3B, a), phos-
phorylated STAT3 showed a tendency to localize adjacent
to blood vessels (Figure 3B, b). Interestingly, immuno-
staining for the cell proliferation marker Ki67 showed the
same pattern as phosphorylated STAT3 (Figure 3B, c).
These results suggested that phosphorylation of STAT3 in
xenograft carcinomas correlates with tumor cell prolifera-
tion and the proximity to blood vessels.
Silencing of endothelial cell-IL-6 is sufficient to inhibit
tumor growth
To investigate whether these in vitro trends have a bio-
logical effect in vivo, we generated xenograft tumors
vascularized with endothelial cells secreting low levels
of IL-6 (HDMEC-shRNA-IL-6) or empty vector control
endothelial cells (Figure 4A). Tumors populated with
HDMEC-shRNA-control grew significantly faster and
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reached 2,000 mm3 at 28 days after implantation, whereas
tumors vascularized with IL-6-silenced endothelial cells
presented approximately half of this size (Figure 4B
and C). Indeed, IL-6 silencing specifically in the vascu-
lar endothelial cells was sufficient to significantly slow
down xenograft tumor growth (Figure 4B and C). Tu-
mors populated with control endothelial cells also pre-
sented significantly higher volume (Figure 4D) and
weight (Figure 4E) than tumors populated with IL-6-
downregulated endothelial cells.
To explore the mechanisms involved in the inhibition
of tumor growth mediated by the silencing of endothelial
cell-IL-6, we analyzed tumor cell proliferation and intra-
tumoral microvessel density by immunohistochemistry.
We observed that expression of the proliferation marker
Ki67 was lower in tumors cells when xenografts were
vascularized with IL-6-silenced endothelial cells (Figure 5A
and B). We also observed a decrease in microvessel
density in tumors vascularized with endothelial cells with
downregulated IL-6 expression, as compared to xenografts
vascularized with control endothelial cells (Figure 5C
and D). Taken together, these results demonstrated that
downregulation of IL-6 in tumor-associated endothelial
cells is sufficient to inhibit tumor growth.
Discussion
A better understanding of the molecular mechanisms
underlying the development and progression of the cer-
vical adenocarcinoma may help to identify novel targets
for pharmacological intervention in this devastating dis-
ease. We have shown that factors secreted by endothelial
cells increase tumor cell survival and migration in vitro
Figure 2 STAT3 phosphorylation induced by endothelial cell-secreted factors is independent of Akt and ERK phosphorylation. Western
blot for phosphorylated and total STAT3, Akt, and ERK in HeLa serum-starved overnight and exposed to A, HDMEC conditioned medium (CM)
or unconditioned medium (EBM) for the indicated time points. In addition, HeLa were pre-incubated for 1 to 2 hours with B, 20 μM Stattic;
C, 20 μM LY294002; or D, 20 μM U0126, and then exposed to HDMEC CM or EBM in presence of the specific inhibitor for the indicated time points.
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[26]. Here, we investigated the impact of endothelial
cell-initiated signaling events to the pathobiology of cer-
vical adenocarcinomas in vivo.
It has been shown that conditioned medium collected
from endothelial cells stimulate phosphorylation of
STAT3, Akt, and ERK in head and neck squamous cell
carcinomas [26]. However, it is not known whether the
ability to activate these pathways was unique to endothe-
lial cells, or if tumor cells themselves could also induce
these signaling events. Several studies describe an auto-
crine effect of tumor cell-secreted factors on cancer pro-
gression [31-33]. Here, we demonstrated that tumor
Figure 3 STAT3 phosphorylation in xenograft human oral squamous cell carcinomas correlates with tumor cell proliferation and
presence of blood vessels. A, HeLa cells were serum-starved overnight and exposed to 20 ng/ml rhIL-6 for the indicated time points. Phosphorylated
and total levels of STAT3, Akt, and ERK were determined by Western blots. B-D, xenograft human tumors were generated in SCID mice by co-implanting
HeLa and HDMEC. Tumors were retrieved after 28 days, and tissues were analyzed by immunohistochemistry: B, total STAT3 with cytoplasmic localization,
diffused through the tissue; C, phosphorylated STAT3 with nuclear localization, concentrated in the proximity of blood vessels; D, Ki67 with nuclear
translocation, localized primarily around blood vessels. Photomicrographs at 200×.
Figure 4 Downregulation of IL-6 in tumor-associated endothelial cells inhibits tumor growth. A, ELISA for IL-6 expression in HDMEC
transfected with shRNA-IL-6 or with a control scrambled oligonucleotide sequence (shRNA-C). B, xenograft human tumors were generated in
SCID mice by co-implanting HeLa and HDMEC-shRNA-IL-6 or control HDMEC-shRNA-C. Tumors growth was analyzed with calipers every 2 days
for the duration of the experiment. C, macroscopic view of two representative xenograft tumors per group. D-E, graphs depicting tumor volume
(D) and tumor weight (E) after retrieval (28 days post-implantation). Asterisk depicts p < 0.05.
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cells exposed to endothelial cell conditioned medium
showed significantly higher levels of STAT3, Akt, and
ERK phosphorylation than tumor cells exposed to condi-
tioned medium collected from tumor cells. Several stud-
ies have shown that deregulation of STAT3, Akt, and
ERK signaling is implicated in tumorigenesis [34-39],
suggesting that aberrant activity of a network of interre-
lated signaling pathways, rather than a single deregu-
lated route, contributes to carcinogenesis. We observed
that while levels of total STAT3, Akt, and ERK were uni-
formly distributed throughout the xenograft tumors,
the expression of phosphorylated STAT3, Akt, and ERK
was more clustered around blood vessels. These results
provide further evidence that endothelial cell-secreted
factors may play a role in the activation of these path-
ways within the tumor microenvironment.
To our knowledge, the crosstalk between STAT3, Akt,
and ERK pathways has not been studied in cervical can-
cer. Trying to understand the relationship between these
endothelial cell-initiated signaling events on tumor cells,
we exposed tumor cells to endothelial cell conditioned
medium in the presence of chemical inhibitors of
STAT3, Akt, and ERK pathways. Our results showed
that endothelial cell-induced Akt and ERK signaling have
a mutually compensatory effect, while STAT3 pathway
appears to be activated independently. These results are
in accordance with accumulating evidence that Akt and
ERK pathways may cooperate to promote the survival of
Figure 5 Downregulation of IL-6 in tumor-associated endothelial cells reduces tumor cell proliferation and decreases intratumoral
microvessel density. A, immunohistochemical analysis for Ki67, indicating tumor cell proliferation in implants containing HeLa and HDMEC-
shRNA-C, or HeLa and HDMEC-shRNA-IL-6. Top panels represent 100× and bottom panels represent 200×. B, quantification of tumor cell proliferation
determined by scoring Ki67 immunostaining. Data represent mean values obtained in random microscopic fields (100×) from 12 tumors per condition.
Asterisk depicts p < 0.05. C, immunohistochemistry for Factor VIII depicting blood vessels (100×). Left panel shows a representative tumor populated
with HeLa and HDMEC-shRNA-C, and right panel shows a tumor containing HeLa and HDMEC-shRNA-IL-6. D, quantification of the microvessel density
in these tumors. Data represent mean values obtained in 10 random microscopic fields per implant (100×) from 12 tumors per condition. Asterisk
depicts p < 0.05. Red arrows point to blood vessels.
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transformed cells, and are alternatively and/or coordi-
nately expressed in several cancers, raising the possibility
that a feedback loop might exist in this network [40-44].
It is well established that activation of the STAT3 sig-
naling pathway promotes tumor growth and expression
of pro-angiogenic factors [45]. We observed that block-
ade of endothelial cell-derived IL-6 inhibited STAT3
phosphorylation in cancer cells [26] and expression of
CXCL8 (IL-8), a potent pro-angiogenic factor that is
strongly correlated with tumor microvessel density [46].
Indeed, despite the fact that endothelial cells secrete
many cytokines and growth factors, silencing of IL-6
with shRNA (or use of a netutralizing antibody) com-
pletely abrogated induced phosphorylation of STAT3 in
tumor cells [26]. Notably, expression of IL-6 is higher in
endothelial cells than in the tumor cells themselves (data
not show). Here, we reported that xenograft tumors
engineered with endothelial cells stably transduced with
shRNA-IL-6 exhibit lower microvessel density. These re-
sults corroborate the hypothesis that IL-6 mediates a
pro-angiogenic paracrine loop that plays an important
role in tumor growth and angiogenesis. In other words,
downregulation of IL-6 secreted by endothelial cells in-
hibits phosphorylation of STAT3 in tumor cells, which
will then secrete less angiogenic factors (e.g. CXCL8)
causing a decrease in tumor microvessel density and
tumor growth.
Notably, tumor cells expressing phosphorylated STAT3
localized primarily adjacent to blood vessels and corre-
lated with expression of the proliferation marker Ki67. We
only analyzed Ki67 positivity adjacent to blood vessels in
both groups to eliminate possible differences due to hyp-
oxia. Expression of Ki67 in tumor cells and tumor micro-
vessel density were lower in tumors vascularized with
IL-6-silenced endothelial cells. Early studies have shown
that Bcl-2 is upregulated in tumor-associated endothelial
cells, that upregulation of Bcl-2 in microvascular endothe-
lial cells accelerates tumor growth, and that endothelial
cells overexpressing Bcl-2 secrete higher levels of IL-6
than vector control cells [25-28] These findings, along
with the results presented here, begin to provide a possible
mechanism for the impact of endothelial cell-derived IL-6
on tumor growth.
Conclusion
Targeted disruption of the vascular endothelium has
been proposed by Dr. Folkman four decades ago and has
shown efficacy in some tumor types [11-13,47]. How-
ever, this approach results in hypoxic, nutrient-deprived
tumor microenvironments that can be associated with
enhanced motility of tumor cells and development of
evasive resistance to therapy [48]. Here, we showed that
specific blockade of the endothelial cell-tumor cell cross-
talk (e.g. IL-6) is sufficient to inhibit tumor growth.
These results suggest that cervical cancer patients might
benefit from the therapeutic blockade of key signaling
events that regulate the crosstalk between endothelial
cells and tumor cells.
Additional file
Additional file 1: Figure S1. Blockade of endothelial cell-induced
STAT3 phosphorylation in tumor cells does not affect Akt and ERK
pathways, whereas inhibition of Akt or ERK has a compensatory
mechanism. HeLa cells were serumstarved overnight and exposed to A,
HDMEC conditioned medium (CM) or unconditioned medium (EBM) for
the indicated time points. In addition, HeLa cells were pre-incubated for
1 to 2 hours with B, 20 μM Stattic, C, 20 μM LY294002, or D, 20 μM
U0126, and then exposed to HDMEC CM or EBM for the indicated time
points. Phosphorylated and total STAT3, Akt, and ERK levels were
determined by Western blot. Figure S2. IL-6 potently activates STAT3
signaling in cervical adenocarcinoma cells. HeLa cells were serum-starved
overnight and exposed to 20 ng/ml rhIL-6 for the indicated time
points. Phosphorylated and total levels of STAT3, Akt, and ERK were
determined by Western blots. A, HeLa cells exposed to rhIL-6. HeLa
cells pre-incubated for 1 to 2 hours with B, 20 μM Stattic; C, 20 μM
LY294002; or D, 20 μM U0126, and then exposed to rhIL-6 for the
indicated time points.
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